Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2022)

Pacira BioSciences has reported Asset Writedowns and Impairment over the past 2 years, most recently at $16.1 million for Q4 2022.

For Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $16.1 million; the TTM value through Dec 2025 reached $16.1 million, down 7.98%, while the annual FY2025 figure was $25.9 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2022 was $16.1 million at Pacira BioSciences, up from $1.4 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $16.1 million in Q4 2022 and troughed at $16.1 million in Q4 2022.